These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 28135567)

  • 21. [Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease].
    Okamoto S
    Rinsho Ketsueki; 2019; 60(9):1205-1211. PubMed ID: 31597845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The first case of thrombocytopenia, anasarca, fever, renal impairment or reticulin fibrosis, and organomegaly (TAFRO) syndrome with unilateral adrenal necrosis: a case report.
    Fujiwara Y; Ito K; Takamura A; Nagata K
    J Med Case Rep; 2018 Oct; 12(1):295. PubMed ID: 30293532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO.
    Phillips AD; Kakkis JJ; Tsao PY; Pierson SK; Fajgenbaum DC
    J Cell Mol Med; 2022 Jun; 26(11):3147-3152. PubMed ID: 35488725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6-year retrospective study.
    Nishimura Y; Hanayama Y; Fujii N; Kondo E; Otsuka F
    Intern Med J; 2020 Feb; 50(2):184-191. PubMed ID: 31211492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort.
    Maisonobe L; Bertinchamp R; Damian L; Gérard L; Berisha M; Guillet S; Fieschi C; Malphettes M; Fadlallah J; Hié M; Dunogué B; De Wilde V; Vandergheynst F; Zafrani L; Grall M; Saada N; Garzaro M; Oksenhendler E; Galicier L; Boutboul D
    Br J Haematol; 2022 Feb; 196(3):599-605. PubMed ID: 34585382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Castleman disease and TAFRO syndrome.
    Masaki Y; Arita K; Sakai T; Takai K; Aoki S; Kawabata H
    Ann Hematol; 2022 Mar; 101(3):485-490. PubMed ID: 35044513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
    Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
    Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
    Pierson SK; Stonestrom AJ; Shilling D; Ruth J; Nabel CS; Singh A; Ren Y; Stone K; Li H; van Rhee F; Fajgenbaum DC
    Am J Hematol; 2018 Jul; 93(7):902-912. PubMed ID: 29675946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment with tacrolimus in TAFRO syndrome: two case reports and literature review.
    Shirai T; Onishi A; Waki D; Saegusa J; Morinobu A
    Medicine (Baltimore); 2018 Jun; 97(23):e11045. PubMed ID: 29879072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature.
    Zhou Q; Zhang Y; Zhou G; Zhu J
    BMC Nephrol; 2020 Nov; 21(1):499. PubMed ID: 33225930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview of Castleman disease.
    Dispenzieri A; Fajgenbaum DC
    Blood; 2020 Apr; 135(16):1353-1364. PubMed ID: 32106302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed diagnosis of TAFRO syndrome: A case report.
    Qiao Y; Zhang X; Xu R; Jia X; Wang Q
    Medicine (Baltimore); 2024 Aug; 103(31):e39148. PubMed ID: 39093747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key.
    Zhou QY
    World J Clin Cases; 2022 Feb; 10(5):1536-1547. PubMed ID: 35211591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome.
    Kurose N; Guo X; Shioya A; Mizutani KI; Kumagai M; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Nakamura S; Yamada S
    Pathol Res Pract; 2019 Oct; 215(10):152563. PubMed ID: 31358479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tufted-angioma-like lesion associated with vascular endothelial growth factor and interleukin-6 in TAFRO syndrome: Is it a common histological feature of multicentric Castleman disease/POEMS syndrome?
    Fujita K; Hatta K
    J Cutan Pathol; 2019 Apr; 46(4):280-284. PubMed ID: 30632181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
    Lust H; Gong S; Remiker A; Rossoff J
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29261. PubMed ID: 34302703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Castleman Disease: A Rare Lymphoproliferative Disorder With Diverse Clinical Presentation, Diagnosis, and Treatment Approach.
    Patel JP; Patel DP; Amin TH; Dave RK; Hardaswani D; Saiyed F; Goswami RJ
    Cureus; 2024 Sep; 16(9):e69149. PubMed ID: 39398672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study.
    Zhang Y; Suo SS; Yang HJ; Zhou XP; You LS; Yu WJ; Wang ZM; Jin J
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):357-365. PubMed ID: 31938902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
    Rubenstein AI; Pierson SK; Shyamsundar S; Bustamante MS; Gonzalez MV; Milller ID; Brandstadter JD; Mumau MD; Fajgenbaum DC
    Br J Haematol; 2024 Mar; 204(3):921-930. PubMed ID: 38168727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology of Castleman Disease.
    Simpson D
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):1-10. PubMed ID: 29157611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.